US · CERS · MEDICAL - DEVICES
Cerus Corporation (CERS) intrinsic value and stock valuation
$1.85as of 2026-11-21 · Mkt cap 457.46M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Cerus Corporation DCF and intrinsic value
InvestorsCraft values CERS with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from CERS’s statements →
Cerus Corporation Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- NeuroPace, Inc. (NPCE) $7.95
- Sight Sciences, Inc. (SGHT) $10.18
- 908 Devices Inc. (MASS) $8.67
- Alpha Teknova, Inc. (TKNO) $7.63
- Senseonics Holdings, Inc. (SENS) $8.02
- RxSight, Inc. (RXST) $4.47
- Quanterix Corporation (QTRX) $1.96
- CVRx, Inc. (CVRX) $0.50
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $206.1M | $180.3M | $156.4M | $162.1M | $130.9M |
| Operating income | -$-8.68M | -$-14.22M | -$-30.05M | -$-34.08M | -$-48.94M |
| Net income | -$-15.63M | -$-20.92M | -$-37.49M | -$-42.78M | -$-54.37M |
| EPSd | -$-82.01K | -$-113.35K | -$-207.97K | -$-242.32K | -$-317.43K |
| Operating cash flow | $11.4M | $11.4M | -$-43.17M | -$-25.61M | -$-33.92M |
| Capital expenditure | -$-2.84M | -$-2.84M | -$-4.6M | -$-2M | -$-910K |
| Free cash flow | $8.52M | $8.52M | -$-47.77M | -$-27.61M | -$-34.83M |
| Total assets | $221.9M | $200.9M | $197.8M | $218.1M | $237.5M |
| Total debt | $97M | $98.1M | $96M | $87.2M | $87.6M |
| Net debt | $77M | $77.8M | $84.4M | $51.7M | $38.8M |
| Total equity | $65M | $56.9M | $53.4M | $68.6M | $85.6M |
| Cash and short-term investments | $82.9M | $80.5M | $65.9M | $102.2M | $129.4M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $206.1M | $180.3M | $156.4M | $162.1M | $130.9M |
| Cost of revenue | $93.8M | $80.8M | $70M | $75M | $63.5M |
| Gross profit | $112.3M | $99.5M | $86.4M | $87.1M | $67.4M |
| Research and development expenses | $67.7M | $58.9M | $67.6M | $64.1M | $63.7M |
| Selling, general and administrative expenses | $80.9M | $75.9M | $75.5M | $83.3M | $81.3M |
| Other expenses | -$-27.66M | -$-21.05M | -$-26.7M | -$-26.27M | -$-28.66M |
| Operating expenses | $121M | $113.8M | $116.5M | $121.2M | $116.3M |
| Cost and expenses | $214.8M | $194.5M | $186.4M | $196.1M | $179.8M |
| Interest income | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest expense | $8.34M | $8.88M | $8.39M | $5.83M | $4.92M |
| Depreciation and amortization | $1.43M | $1.85M | $2.6M | $2.98M | $3.15M |
| Ebitda | -$-5.51M | -$-10.02M | -$-26.34M | -$-33.52M | -$-45.99M |
| Operating income | -$-8.68M | -$-14.22M | -$-30.05M | -$-34.08M | -$-48.94M |
| Total other income/expenses, net | -$-6.6M | -$-6.53M | -$-7.27M | -$-8.26M | -$-5.12M |
| Income before tax | -$-15.28M | -$-20.76M | -$-37.32M | -$-42.34M | -$-54.06M |
| Income tax expense | $350K | $200K | $330K | $490K | $320K |
| Net income | -$-15.63M | -$-20.92M | -$-37.49M | -$-42.78M | -$-54.37M |
| Weighted average shares outstanding | $190.6M | $184.6M | $180.3M | $176.5M | $171.3M |
| Weighted average diluted shares outstanding | $190.6M | $184.6M | $180.3M | $176.5M | $171.3M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $82.9M | $80.5M | $65.9M | $102.2M | $129.4M |
| Net receivables | $30.4M | $29.8M | $35.5M | $34.4M | $25.1M |
| Inventory | $56.1M | $38.2M | $39.9M | $29M | $26.8M |
| Total current assets | $174.4M | $152M | $144.4M | $170.1M | $187.1M |
| Property, plant and equipment, net | $19.3M | $15.5M | $19.4M | $23.5M | $25.2M |
| Goodwill and intangible assets | $1.32M | $1.32M | $1.32M | $1.32M | $1.32M |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $47.5M | $48.9M | $53.3M | $48M | $50.4M |
| Total assets | $221.9M | $200.9M | $197.8M | $218.1M | $237.5M |
| Accounts payable | $28M | $21.7M | $23.8M | $33M | $35.6M |
| Short-term debt | $46.3M | $21.6M | $22.5M | $58.3M | $16.6M |
| Deferred revenue | $1.27M | $1.4M | $2M | $590K | $670K |
| Total current liabilities | $100.8M | $63.6M | $67.5M | $117.1M | $78.6M |
| Long-term debt | $50.7M | $76.5M | $73.6M | $29M | $71M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $56.1M | $80.4M | $76.8M | $32.5M | $73.3M |
| Capital lease obligations | $13.1M | $13.9M | $16.2M | $17.4M | $18.2M |
| Total liabilities | $156.9M | $144M | $144.3M | $149.5M | $151.9M |
| Common stock | $190K | $190K | $180K | $180K | $170K |
| Retained earnings | -$-1.08B | -$-1.07B | -$-1.04B | -$-1.01B | -$-964.34M |
| Accumulated other comprehensive income (loss) | -$-160K | -$-400K | -$-1.27M | -$-2.79M | -$-150K |
| Total equity | $65M | $56.9M | $53.4M | $68.6M | $85.6M |
| Total investments | $62.9M | $60.2M | $54.2M | $66.6M | $80.6M |
| Total debt | $97M | $98.1M | $96M | $87.2M | $87.6M |
| Net debt | $77M | $77.8M | $84.4M | $51.7M | $38.8M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-15.63M | -$-20.96M | -$-37.49M | -$-42.83M | -$-54.38M |
| Depreciation and amortization | $1.85M | $1.85M | $2.6M | $2.98M | $3.15M |
| Stock-based compensation | $22.9M | $22.9M | $20.3M | $24.5M | $23.6M |
| Change in working capital | -$-6.83M | $5.23M | -$-32.03M | -$-16.05M | -$-9.4M |
| Accounts receivable | -$-400K | $5.5M | -$-1.1M | -$-9.2M | -$-4.21M |
| Inventory | -$-14.68M | $7.03M | -$-14.95M | -$-1.77M | -$-19.61M |
| Accounts payable | $5.72M | -$-1.48M | -$-7.33M | -$-4.91M | $12.2M |
| Net cash provided by operating activities | $11.4M | $11.4M | -$-43.17M | -$-25.61M | -$-33.92M |
| Investments in property, plant and equipment | -$-2.84M | -$-2.84M | -$-4.6M | -$-2M | -$-910K |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | -$-10.46M | $910K |
| Net cash used for investing activities | -$-8.13M | -$-8.13M | $8.62M | $8.46M | $12.7M |
| Common stock issued | $560K | $670K | $0.00 | $0.00 | $2.74M |
| Common stock repurchased | $0.00 | $0.00 | -$-170K | -$-100K | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $4.96M | $4.96M | $10.7M | $4.19M | $34.3M |
| Net change in cash | $8M | $8M | -$-24M | -$-13.69M | $12.1M |
| Cash at end of period | $21.4M | $21.4M | $13.4M | $37.4M | $51M |
| Operating cash flow | $11.4M | $11.4M | -$-43.17M | -$-25.61M | -$-33.92M |
| Capital expenditure | -$-2.84M | -$-2.84M | -$-4.6M | -$-2M | -$-910K |
| Free cash flow | $8.52M | $8.52M | -$-47.77M | -$-27.61M | -$-34.83M |
Line items
Line items
Line items
About Cerus Corporation
Cerus Corporation operates as a biotechnology firm dedicated to advancing and marketing the INTERCEPT Blood System. This proprietary technology significantly enhances the safety of transfusable blood components by neutralizing biological threats, thereby reducing the risk of blood-borne pathogens. The company's product line includes INTERCEPT systems specifically engineered to deactivate pathogens in donated platelets and plasma. It also offers a dedicated INTERCEPT Blood System for the inactivation of harmful agents in red blood cell components. Furthermore, Cerus markets an INTERCEPT Blood System for Cryoprecipitation, which leverages its plasma technology to produce two key pathogen-reduced blood products: a cryoprecipitated fibrinogen complex for treating and controlling bleeding, particularly massive hemorrhages stemming from fibrinogen deficiency, and pathogen-reduced, cryoprecipitate-reduced plasma. Cerus distributes these platelet and plasma systems globally through a combination of its direct sales force and an extensive network of distributors, reaching markets in North America, Europe, the Commonwealth of Independent States, the Middle East, and Latin America. Established in 1991, Cerus Corporation maintains its corporate headquarters in Concord, California.
- CEO
- Vivek K. Jayaraman
- Employees
- 275
- Beta
- 1.77
Explore
Frequently asked questions
What is the intrinsic value of Cerus Corporation (CERS)?
Cerus Corporation (CERS) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is CERS undervalued?
CERS trades at a price of $1.85 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.